REPLICEL LIFE SCIENCES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0428 USD | +4.99% |
|
-.--% | -4.89% |
| Apr. 18 | RepliCel Life Sciences Inc. Announces Secured Loan Agreement | CI |
| 2023 | RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 8.399 | 9.651 | 8.744 | 7.257 | 8.826 | 2.977 |
| Enterprise Value (EV) 1 | 7.902 | 7.232 | 9.141 | 7.8 | 9.233 | 3.277 |
| P/E ratio | -1.21 x | -2.95 x | -2.67 x | -3.69 x | -1.83 x | -3.54 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | 79,684,387 x | 34,615,163 x | 20,516,305 x | 24,950,081 x | 8,416,352 x |
| EV / Revenue | - | 59,715,424 x | 36,185,210 x | 22,049,051 x | 26,101,234 x | 9,264,363 x |
| EV / EBITDA | -1.32 x | -2.64 x | -3.03 x | -5.78 x | -4.01 x | -2.35 x |
| EV / FCF | -2.54 x | -5.71 x | -4.59 x | -29.7 x | -5.48 x | -5.64 x |
| FCF Yield | -39.4% | -17.5% | -21.8% | -3.37% | -18.3% | -17.7% |
| Price to Book | -26.1 x | -21.2 x | -2.75 x | -1.28 x | -1.17 x | -0.56 x |
| Nbr of stocks (in thousands) | 21,543 | 26,800 | 30,646 | 33,523 | 38,531 | 42,750 |
| Reference price 2 | 0.3899 | 0.3601 | 0.2853 | 0.2165 | 0.2291 | 0.0696 |
| Announcement Date | 4/30/18 | 4/30/19 | 7/31/20 | 4/30/21 | 6/28/22 | 5/1/23 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales | - | 0.1211 | 0.2526 | 0.3537 | 0.3537 | 0.3537 |
| EBITDA 1 | -5.988 | -2.736 | -3.016 | -1.349 | -2.3 | -1.395 |
| EBIT 1 | -5.992 | -2.739 | -3.018 | -1.35 | -2.301 | -1.396 |
| Operating Margin | - | -2,261.75% | -1,194.67% | -381.75% | -650.57% | -394.51% |
| Earnings before Tax (EBT) 1 | -6.014 | -2.769 | -2.954 | -1.58 | -4.073 | -0.7432 |
| Net income 1 | -6.014 | -2.769 | -2.954 | -1.58 | -4.073 | -0.7432 |
| Net margin | - | -2,286.34% | -1,169.3% | -446.74% | -1,151.52% | -210.11% |
| EPS 2 | -0.3220 | -0.1222 | -0.1067 | -0.0586 | -0.1254 | -0.0197 |
| Free Cash Flow 1 | -3.116 | -1.266 | -1.994 | -0.2627 | -1.686 | -0.5806 |
| FCF margin | - | -1,045.47% | -789.18% | -74.26% | -476.61% | -164.14% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/30/18 | 4/30/19 | 7/31/20 | 4/30/21 | 6/28/22 | 5/1/23 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 0.4 | 0.54 | 0.41 | 0.3 |
| Net Cash position 1 | 0.5 | 2.42 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | -0.1315 x | -0.402 x | -0.177 x | -0.2151 x |
| Free Cash Flow 1 | -3.12 | -1.27 | -1.99 | -0.26 | -1.69 | -0.58 |
| ROE (net income / shareholders' equity) | -1,357% | 714% | 175% | 33.3% | 68.4% | 11.7% |
| ROA (Net income/ Total Assets) | -280% | -84.1% | -103% | -182% | -284% | -125% |
| Assets 1 | 2.147 | 3.294 | 2.855 | 0.8673 | 1.434 | 0.5922 |
| Book Value Per Share 2 | -0.0100 | -0.0200 | -0.1000 | -0.1700 | -0.2000 | -0.1200 |
| Cash Flow per Share 2 | 0.0200 | 0.0900 | 0 | 0 | 0.0100 | 0.0100 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 4/30/18 | 4/30/19 | 7/31/20 | 4/30/21 | 6/28/22 | 5/1/23 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -4.89% | 2.78M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- REPCF Stock
- Financials RepliCel Life Sciences Inc.
